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Background: Shoulder pain is a common musculoskeletal symptom with a wide range of potential causes;
however, the majority of conditions can be managed with conservative treatment. The aim of this study is to assess
the efficacy and safety of Traumeel injections versus corticosteroid injections and placebo in the treatment of
rotator cuff syndrome and bursitis and expand the current evidence base for the conservative treatment of rotator
cuff syndrome.
Methods/Design: This is a multi-center, randomized, double-blind, 16-week, three-arm, parallel-group, active- and
placebo-controlled trial to assess the efficacy and safety of Traumeel 2 ml injection versus dexamethasone 8 mg
injection versus placebo (saline solution). Patients will be randomly allocated to Traumeel, dexamethasone or placebo
in a 2:2:1 randomization. After 1 week screening, patients will receive 3 injections at weekly intervals (days 1, 8 and 15)
with additional follow-up assessments on day 22, a telephone consultation in week 9 and a final visit at week 15. Male
and female patients aged 40 to 65 years, inclusive, will be recruited if they have acute episodes of chronic rotator cuff
syndrome and/or bursitis. Patients with calcifications in the shoulder joint or a complete rotator cuff tear will be
excluded. At least 160 patients will be recruited. All subacromial injections will be performed under ultrasound
guidance utilizing a common technique. The only rescue medication permitted will be paracetamol (acetaminophen),
with usage recorded. The primary endpoint is change from baseline in abduction-rotation pain visual analog scale
(0–100 mm scale, 0 corresponds to no pain and 100 to extreme pain) at day 22 (Traumeel injections versus
dexamethasone injections) for active external rotation. Secondary efficacy parameters include range of motion,
disability of arm, shoulder, hand score and patient’s/investigator’s global assessment. Clinical efficacy will be assessed as
non-inferiority of Traumeel with respect to dexamethasone regarding the primary efficacy parameter.
Discussion: It is hoped that the results of this trial will expand the treatment options and evidence base available for
the management of rotator cuff disease.
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Shoulder pain is the third most common musculoskeletal
symptom encountered in medical practice, after back and
neck pain [1]. It accounts for almost 3 million patient
visits each year in the USA [2,3]. A wide range of potential
pathoanatomic entities, from simple sprains to massive
rotator cuff tears, can give rise to shoulder pain [2].
The majority of these conditions can be managed with
conservative treatment [2,4], and conservative therapy can
include a number of novel treatments [5]. Rotator cuff
dysfunction is a particularly important entity because it
occurs frequently, and indicative with complete tear, may
necessitate surgical treatment [2,6,7].
The shoulder has the greatest range of motion (ROM)
of any joint in the human body. Size mismatch between
the smaller glenoid and larger humeral head creates a
risk of instability. Stability is provided both statically by
the capsule and labrum, and dynamically by the rotator
cuff musculature. Dysfunction of any of these structures
can lead to pain, weakness, and instability.
The rotator cuff is a musculo-tendinous confluence of
four muscles that initiate shoulder motion and maintain
the normal relationship between the articular surfaces.
The supraspinatus muscle provides abduction, the infra-
spinatus and teres minor muscles provide external ro-
tation, and the subscapularis muscle provides internal
rotation. In addition, the muscles of the rotator cuff bal-
ance the forces of other shoulder muscles, most import-
antly the deltoid muscle. Contraction of the deltoid
muscle in the absence of supraspinatus function leads to
superior translocation of the humeral head, making wide
abduction difficult.
Non-operative treatment for shoulder pain due to rotator
cuff impingement and tears generally includes appropriate
physical therapy, anti-inflammatory medication, cortico-
steroid injections, and other approaches. Meta-analyses of
trials of subacromial injection of corticosteroids for rotator
cuff disease have shown a beneficial effect over placebo,
while evidence for other interventions is lacking [6,8,9].
The importance of the accuracy of injecting the subacro-
mial bursa with corticosteroids was highlighted by a study
by Henkus et al. [10] showing that despite the confidence
of physicians, without guidance many subacromial injec-
tions hit surrounding structures. However, only injection
directly into the subacromial bursa resulted in significant
pain relief and increase in functional scores. Marder et al.
[11] further supported these findings and found that the
rate of accuracy varied with route of injection, and anterior
and lateral routes are more accurate than the posterior
route. Due to potential variance in accuracy of subacromial
injection between physicians, ultrasound-guided injections
utilizing a common method have been used for this study.
Traumeel (Tr14) injection solution is a combination
formula of 12 botanical and 2 mineral substances withdemonstrated anti-inflammatory, anti-edematous, anti-
exudative properties. The exact mechanism of action of
Tr14 injection solution is still to be fully understood.
Various cellular and biochemical pathways appear to be
modulated by the ingredients. It has been suggested that
Tr14 injection solution does not inhibit cyclo-oxygenase
(COX) or lipoxygenase enzyme pathways, as is the case
with non-steroidal anti-inflammatory drugs (NSAIDs)
[12]. In the rat model of blood-induced inflammation, Tr14
injection solution significantly reduced hind paw induced-
edema and decreased IL-6 production. The authors sug-
gested that Tr14 injection solution seems to act by speeding
up the healing process instead of blocking the develop-
ment of edema from the beginning [13]. Additional
basic research is currently underway to further elucidate
Tr14 injection solution’s mechanism of action.
Tr14 injection solution has been shown to be effective
for hemarthrosis of the knee [14], epicondylitis [15], and
various musculoskeletal injuries [16]. However, no large
study with Tr14 injection solution has been performed
so far in patients with rotator cuff syndrome and bur-
sitis. Thus, the aim of this study is to assess the efficacy
and safety of Tr14 injection solution injections versus
corticosteroid injections in the treatment of rotator cuff
syndrome and bursitis and expand the current evidence
base for the conservative treatment of the rotator cuff
syndrome. It is hoped that the results of this trial will ex-
pand the treatment options available to clinicians for the
treatment of rotator cuff syndrome, allowing greater
patient choice.
Methods/Design
This will be a multi-center, randomized, double-blind,
16-week, three-arm, parallel-group, active- and placebo-
controlled trial to assess the efficacy and safety of Tr14
injection solution 2 ml injection versus dexamethasone
8 mg injection versus placebo (Figure 1).
The objective of this study is to evaluate reduction of
pain and improvement of functional motion parameters in
patients with rotator cuff syndrome and bursitis treated
with Tr14 injection solution injections versus corticoster-
oid injections and versus placebo.
Patients will be randomly allocated to Tr14 injection so-
lution, dexamethasone or placebo in a 2:2:1 randomization.
The randomization will be stratified by site. Randomization
codes will be generated by a statistician not involved in the
study from an algorithm based on the PROC PLAN pro-
cedure of SAS, Version 9.1.3. Sealed envelopes containing
the individual codes will be sent to the centers and to the
study sponsor for the purposes of assigning kits to patients
and the managing of adverse events.
All study personnel and patients will be blinded to the
treatment being used during the study. The investigator
will keep the treatment code envelopes throughout the
Figure 1 Patient flow through the study.
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valid reason, e.g. in the case of emergency, should stop-
ping the blinded medication be considered insufficient
to manage the individual patient. All study medication
will be supplied in 2 ml vials ready for injection, and
packaging and labeling will be carried out in accordance
with the requirements of Annex 13 of the Good Manu-
facturing Practice (GMP) guidelines, International Con-
ference on Harmonization (ICH) Good Clinical Practice
(GCP) requirements, sponsor approved standard operat-
ing procedures, the European Union (EU) Clinical Trial
Directive and all applicable local laws.
The study includes 2 sites in Belgium, 4 in Germany,
and 4 in Spain, all based in outpatient clinics. The study
has been approved by Competent Authorities in all three
countries (Federal Agency for Medicines and Health
Products in Belgium, Bundesinstitut für Arzneimittel and
Medizinprodukte in Germany and the Agencia Espaňola
del Medicamento in Spain), and has received ethical
approval from relevant bodies in each country (Commissievoor Medische Ethiek Universitair Zirkenhuis Ghent in
Belgium, Ethikkommission der Ärztekammer Hamburg in
Germany and Comité Ético de Investigación Clinica
Complejo Hospitalario de Toledo in Spain).
The study will be conducted in compliance with the
ethical principles of the Declaration of Helsinki and its
amendments as adopted by the 59th World Medical As-
sembly (WMA) General Assembly, Seoul, October 2008;
the principles of the GCP provided in the ICH Harmo-
nised Tripartite Guidelines for GCP 1996; and all applic-
able national laws and regulations.
Participants
Male and female patients aged 40 to 65 years, inclusive,
will be recruited if they have acute episodes of chronic ro-
tator cuff syndrome and/or bursitis: tendinopathy of the
supraspinatus tendon, bursitis, or partial degenerative
tears of the supraspinatus and/or infraspinatus tendon
(differentiation by ultrasonography). They must be willing
and able to understand and sign an approved informed
Table 1 Components of Tr14 injection solution
Source of extract Quantity per 2 mL
injection solution
Achillea millefolium (milfoil) 0.002 μL
Aconitum napellus (monkshood) 0.012 μL
Arnica montana (mountain arnica) 0.02 μL
Atropa belladonna (deadly nightshade) 0.02 μL
Bellis perennis (daisy) 0.01 μL
Calendula officinalis (calendula) 0.02 μL
Matricaria recutita (chamomile) 0.002 μL
Echinacea angustifolia (narrow-leaved
cone flower)
0.005 μL
Echinacea purpurea (purple cone flower) 0.005 μL
Hamamelis virginiana (witch hazel) 0.02 μL
Calcium sulphide (otherwise: Hepar sulfuris) 0.000002 μL
Hypericum perforatum (St John’s wort) 0.006 μL
Mercurico-amidonitrate (otherwise:
Mercurius solubilis Hahnemanni)
0.000001 μL
Symphytum officinale (comfrey) 0.000002 μL
Excipients 0.9% saline solution
Tr14 = Traumeel.
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(as proven by negative pregnancy test before first study
drug administration) or breast-feeding. Females of child-
bearing potential (including those less than one year post-
menopausal) must agree to maintain reliable birth control
throughout the study, i.e. an established use of oral,
injected or implanted hormonal contraception, female
sterilization by hysterectomy, bilateral oophorectomy, or
bilateral tubal exeresis, intrauterine device (IUD) or coil or
barrier method (e.g. diaphragm, cervical/vault cap) plus
spermicidal cream/gel.
Potential study patients will be excluded if one of the
following exclusion criteria is present: calcifications in
shoulder joint; complete rotator cuff tears; treatment with
NSAIDs (previous treatment with NSAIDs is allowed,
with a wash-out period of 1 week; paracetamol [acet-
aminophen] can be taken until 48 hours before baseline
visit); corticosteroid therapy by mouth or by injection
within the previous 3 months prior to screening; any
contraindication for corticosteroid therapy; physical ther-
apy, acupuncture, transcutaneous electrical nerve stimula-
tion (TENS) and shock-wave therapy (within 30 days prior
to screening); treatment with anticoagulants (except low-
dose aspirin); diabetic patients including borderline cases
(glycosylated fraction of hemoglobin [HbA1c] >7.0% at
screening); clinically significant shoulder joint deformities;
major injury, including sports-related injury, to the shoul-
der within the past year; significant osteoarthritis of the
shoulder; cervical spine disorder (that could confound the
clinical assessment) that has been symptomatic and re-
quired active treatment within the past 3 months before
screening; any active musculoskeletal disease that could
confound the diagnosis/evaluation of the painful shoulder,
any neurological etiology of the pain, or any acute infec-
tion of the shoulder joint; any major surgery, arthroplasty,
or arthroscopy in the signal shoulder within 6 months of
screening or planned surgery within the duration of the
study; prior history of any malignancy (with the exception
of basal cell carcinoma) treated less than 2 years ago;
patients with rheumatic polymyalgia; known or suspected
allergies against one or any particular ingredients of any of
the study preparations; presence of serious gastrointestinal,
renal, hepatic, pulmonary, cardiovascular, neurological dis-
ease or other known systemic disease (like leukemia,
tuberculosis, immune mediated diseases, multiple scler-
osis, Acquired Immuno Deficiency Syndrome, Human
Immunodeficiency Virus-infections or other chronic virus
infections) that might interfere with the outcome of the
study or the patient’s ability to comply with study require-
ments; presence of infections and/or skin diseases in the
area of the injection site (including psoriasis); clinically
significant abnormal laboratory values (as judged of the
investigator) at the screening visit; consumption of any in-
vestigational product within 1 month prior to the screeningvisit; and patients who are likely to be non-compliant
or uncooperative during the study, as judged by the
investigator.
Recruitment
The recruitment phase will be completed when 160 pa-
tients have been enrolled, and the duration of this re-
cruitment period will be about 12 months. Patients will
be recruited from the existent patient pools at the trial
centers. They will be outpatients attending for a sched-
uled visit who would then be asked about their willing-
ness to be included in a clinical trial.
Interventions
All interventions will be provided in 2 ml vials, identical
in appearance. Traumeel® injection solution (Biologische
Heilmittel Heel GmbH) is officially classified as a homeo-
pathic medicinal product [17]. Tr14 injection solution is a
formulation of 12 botanical and 2 mineral substances. The
quantities of each component are shown in Table 1. Dexa-
methasone 8 mg will be provided as Fortecortin® (Merck
Pharma GmbH) and placebo will be saline solution in
2 ml vials.
Participants will receive 3 injections at weekly intervals
on visits 2, 3 and 4. All investigators were trained in
ultrasound-guided injection technique at an investigator’s
meeting in Ghent, Belgium, to ensure consistency of ad-
ministration. The patient is placed in a supine position to
reduce any risk of syncope during the procedure. Ultra-
sound guidance using a sagittal view (7 till 14 MHz)
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guide the injection into the subacromial bursa with the
ultrasound probe used in a long-axis lateral view. A nar-
row gauge needle should be used (22–30 gauge). The nee-
dle is advanced until its tip penetrates the bursal cavity.
Images are taken before and after injection, showing dis-
tension of the bursa following injection of the product.
For the first 48 hours after injection, the patient is allowed
to continue all routine activities of daily living, but is
advised not to overuse the treated shoulder.Concomitant care
Previous treatment with NSAIDs, analgesics, and COX
type 2 (COX-2) inhibitors is allowed, with a washout
period of 1 week before baseline; paracetamol can be
taken until 48 hours before baseline visit. This also in-
cludes all kinds of applications, i.e. topical, oral or paren-
teral. Patients have to be instructed that for the duration
of the study they must not take any pain relief medica-
tion other than paracetamol (which will be used as res-
cue medication and can be taken during the study except
48 hours before the study visits). No chondroprotective
medication is allowed (e.g. among others, glucosamine,
chondroitin sulfate, hyaluronic acid, diacerein, native
collagen and so-called USA-300 preparation).
Treatment with anticoagulants is not permitted during
the study. Low-dose (70–100 mg/d) aspirin for anti-
thrombotic therapy is permitted if doses are stable for the
month prior to screening and remain stable throughout
the study period. Also, treatment with corticosteroid injec-
tions or intake of oral corticosteroids in the 3 months
prior to the study or during the study is not permitted.
Physiotherapy is forbidden within 30 days prior to screen-
ing, but will be allowed as non-drug rescue treatment from
Day 23 until Week 15. Acupuncture, TENS and shock-
wave therapy are also forbidden within 30 days prior to
screening and during the course of the study until week 15.
After screening, only paracetamol (500 mg when ne-
cessary) is permitted during the study as rescue medica-
tion for pain relief. At screening, after ensuring patient
eligibility, paracetamol rescue medication and a patient
diary will be provided to the patients. Patients will be
instructed to document the paracetamol consumption
every day and to bring the diary to the site at each visit,
where paracetamol usage will be documented. Paraceta-
mol consumption is limited to 2000 mg (4 tablets) per
day. Patients are instructed that they must not take para-
cetamol within the 48 hours prior to a study visit.Criteria for withdrawal of patient from study
Study completion or discontinuation will be documented
with the reason for any discontinuation. Reasons for a
patient discontinuing participation in the study include: Inefficacy of the study therapy:
 Increase of visual analog scale (VAS) by at least
30 mm in comparison to baseline during 2
consecutive visits
 Any other medical condition requiring – in the
opinion of the investigator – a change of the
therapy for the baseline condition
 Occurrence of a medical condition requiring use of
prohibited medications (NSAIDs, analgesics other
than paracetamol, COX-2 inhibitors, chondroprotec-
tive medications, anticoagulants other than low-dose
aspirin or corticosteroids other than study therapy)
 Medical condition affecting assessment of the
primary endpoint (e.g. any injuries or conditions
causing shoulder pain or requiring analgesic
treatment)
 Medical conditions affecting patient safety if
participation with the study therapy is continued:
conditions and adverse events (AEs) causing safety
concerns with intra-articular steroids therapy or
with injection to the shoulder joint area OR any other
AE or condition that – in the opinion of the investiga-
tor – endangers patient safety if the participation in
the study is continued
 Withdrawal of consent
 Lost to follow-up
 Death.
In case of an AE, the patient is to be followed up until
resolution of the AE. Patients who discontinue prema-
turely from the study will not be replaced.Adherence to protocol
Protocol adherence will be documented and judged by
patient reporting (diary) and attendance at clinic visits
according to schedule.Outcomes
The primary endpoint is change from baseline in
abduction-rotation pain VAS (0–100 mm scale, 0 cor-
responds to no pain and 100 to extreme pain) at visit
5 (day 22) (Tr14 injection solution injections versus
dexamethasone injections) for active external rotation.
The abduction-rotation will be done with an internal
rotation and external rotation and both actively and
passively. However, the primary parameter is active ro-
tation abduction with external rotation and only for
this movement the VAS will be measured. During the
shoulder examination, the active external abduction
rotation must be the first movement during evaluation
for pain VAS determination.
Secondary efficacy parameters include ROM, disabil-
ity of arm, shoulder, hand (DASH) score and patient’s/
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movements will be analyzed [18,19]:
 Abduction rotation (active external, active internal,
passive external, passive internal) measured by
goniometry.
 Hand-back range and hand-neck range both
measured in cm.
 Jobe (also known as ‘empty can’) test with
measurement of pain and weakness (positive/
negative). This will be examined as active
movement.
 Painful arc after visit 4 (last injection) with
measurement of pain (positive/negative). This
will be examined as active movement.
Safety parameters include local tolerability, laboratory
monitoring, vital signs and AEs. AEs will be standardized
for terminology and classification, using Medical Diction-
ary for Regulatory Activities (MedDRA) (the latest available
version will be used). Concomitant medications will be
classified by site of action and therapeutic and clinical
characteristics using the World Health Organization
(WHO) DRUG dictionary (the latest available version
will be used).
Participant timeline
A schedule of study procedures and events is provided
in Table 2.
Statistical methods
Clinical efficacy will be assessed as non-inferiority of
Tr14 injection solution with respect to dexamethasone
regarding the primary efficacy parameter. A one-sided
test of non-inferiority of Tr14 injection solution with re-
spect to dexamethasone at level 0.025 will be computed
using an analysis of covariance (ANCOVA) model with
treatment group and center as qualitative factors and
the baseline value of the abduction rotation pain VAS
for active external rotation as a covariate.
All continuous efficacy parameters will be analyzed by
suitable analysis of ANCOVA models, whereas the dichot-
omous Jobe and painful arc test data will undergo suitable
logistic regression model analyses. The ordered categorical
responses of the patients’ and examiners’ global assess-
ment will be evaluated by Cochran-Mantel-Haenszel
(CMH) tests that account for stratification by center. Clin-
ical safety will be addressed by assessing AEs, physical
examinations, laboratory assessments, and vital signs re-
sults in a descriptive manner. All statistical analyses in this
study will be exploratory in nature.
Analyses will be based on the safety analysis, full ana-
lysis, and the per-protocol sets. The summaries of the
efficacy parameters, the statistical analyses of the primaryefficacy variable, and the statistical analyses of the second-
ary efficacy variables will be performed on the per-protocol
set. These summaries and analyses will be supported by
corresponding summaries and exploratory statistical ana-
lyses performed on the full analysis set. Missing values for
all efficacy parameters will be imputed by the last observa-
tion carried forward (LOCF) approach. All statistical tests
will be supported by presenting estimates and 95% confi-
dence intervals for the respective treatment effects and dif-
ferences between the treatment groups. These estimates
and confidence intervals will be based on the respective
statistical models used for the analysis, shown in Table 3.
Sample size calculation
Estimation of sample size is based on the primary efficacy
variable, change from baseline in abduction rotation pain
VAS for active external rotation. A one-sided t-test of
non-inferiority at level 0.025 based on a non-inferiority
margin of 13 mm and a standard deviation of 25 mm for
the response variables achieves a power of 80% computed
for equal treatment effects if the sample size is set to 60
patients per active treatment group in the per protocol
set. Assuming a dropout rate of 6.25%, at least 160
patients should be randomized (i.e. 64 patients per active
treatment group and 32 in the placebo group).
Discussion
The corticosteroids most commonly used in clinical tri-
als for problems with the rotator cuff are methylprednis-
olone acetate and triamcinolone acetonide [8]. However,
as crystalline corticosteroids, the appearance of these
products in the vial is considerably different to Tr14 in-
jection solution. Dexamethasone was chosen as the com-
parator corticosteroid as visually the solution is similar
to Tr14 injection solution, thus aiding blinding of those
administering the injections. The dose of dexamethasone
was chosen to provide equivalence to 40 mg methyl-
prednisolone acetate or 40 mg triamcinolone acetonide
[20]. This dose of dexamethasone also provided a 2 ml
injection, which was the same as the quantity of Tr14
injection solution to be used, again assisting blinding. A
once-weekly dosing interval was chosen as an appropri-
ate time interval to allow comparison with other injec-
tion therapies. A total of three injections was chosen as,
in clinical practice, if there are no signs of improvement
after 3 weeks of injections, it is unlikely that treatment
would be continued.
To the best of our knowledge, dexamethasone has only
been investigated in shoulder injuries on two previous occa-
sions, first by Plafki et al. [21] using 4 mg dexamethasone-
21-palmitat (equivalent to 2.5 mg dexamethasone) injected
into the subacromial bursa once with ultrasound guidance
for the treatment of subacromial impingement. This study
was hindered by the need to stop the local anesthetic only
Table 2 Schedule of study procedures and events
Visit 1
Screening (max. –7 days)
Visit 2
Baseline Day 1
Visit 3
Day 8 ± 1 day
Visit 4
Day 15 ± 1 day
Visit 5
Day 22 ± 1 day
Telephone
Week 9 ± 3 days
Visit 7
Week 15 ± 3 days
Informed consent X
Inclusion/exclusion review X X
Body weight and height X
Physical examination X X
Vital signs X X X X X X
Medical history X*
Randomization X
Shoulder ultrasonography X X**** X**** X****
Urine for pregnancy test X X
Clinical laboratory tests X X
Telephone visit X
Shoulder examination including***
○ VAS score X X X X X X
○ DASH score
○ Range of motion*****
○ Jobe/painful arc test
Patient’s global assessment X X
Investigator’s global assessment X X
Shoulder injections X X X
Previous and concomitant treatments* X* X X X X X X
Rescue medication dispensation X X X X X
Patient diary dispensation X
Rescue medication consumption** X X X X X
Patient diary collection X
Study drug accountability X X X X X
AEs X X X X X X X
*Patients are to be instructed to discontinue their current pain medication (NSAIDs, analgesics, COX-2 inhibitors) one week prior to baseline visit. No chondroprotective medication is allowed (e.g., among others,
glucosamine, chondroitin sulfate, hyaluronic acid, diacerein, native collagen and so-called USA-300 preparation).
**The usage of study rescue medication is generally not allowed within 48 hours before a study visit. At each visit, the patient has to bring the diary with documentation of daily consumption to the site.
***Bilateral shoulder examination at screening (VAS in target shoulder only).
****Ultrasound-guidance of subacromial periarticular study drug injections.
*****Range of motion includes abduction rotation (active external, active internal, passive external, passive internal) measured by goniometry and hand-back range and hand-neck range both measured in cm. The
active external abduction rotation must be the first movement during shoulder examination for pain VAS determination.
AE = adverse event; COX-2 = cyclo-oxygenase type 2 inhibitors; DASH = Disability of arm, shoulder, hand; NSAID = non-steroidal anti-inflammatory drug; VAS = visual analog scale.
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Table 3 Statistical analyses to be performed
ANCOVA with treatment
group and center as
qualitative factors and
baseline value as
covariate
Applicable for analyses at visits 5 and 7 for
both treatment comparisons Tr14 injection
solution against the comparators
dexamethasone and placebo, respectively
• Change from baseline in abduction-rotation
pain VAS for active external rotation
• Changes from baseline in ROM for
abduction rotation as goniometry in
degrees (active external, active internal,
passive external, passive internal rotation)
• Changes from baseline in ROM for hand-
back range and hand-neck range as
distance measurement in cm
• Changes in DASH
Repeated measurements
ANCOVA with treatment
group, center, visit and
treatment-by-visit
interaction as qualitative
factors and baseline
value as covariate
Visits 5 and 7 included in analysis; both
treatment comparisons Tr14 injection
solution against the comparators
dexamethasone and placebo, respectively:
• Change from baseline in abduction-rotation
pain VAS for active external rotation
Logistic regression model
with treatment group,
center and baseline value
(positive/negative) as
qualitative factors
Applicable for analyses at visits 5 and 7 for
both treatment comparisons Tr14 injection
solution against the comparators
dexamethasone and placebo, respectively:
• Jobe
• Painful arc
Cochran-Mantel-Haenszel
(CMH) test for ordered
categorical responses
stratified by center
Applicable for analyses at visits 5 and 7 for
both treatment comparisons Tr14 injection
solution against the comparators
dexamethasone and placebo, respectively:
• Patient’s global assessment
• Investigator’s global assessment
ANCOVA = analysis of covariance; DASH = disability of arm, shoulder, hand;
ROM = range of motion; Tr14 = Traumeel; VAS = visual analog scale.
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rendering the arm ethically unacceptable. However, results
in both dexamethasone and triamcinolone acetate (10 mg)
treatment groups were similar, suggesting that dexametha-
sone can provide similar results to triamcinolone acetate.
The authors conclude that subacromial steroid injections
could prevent the need for surgery in at least half of
patients with chronic subacromial impingement syndrome.
The second study by Shibata et al. [22] was conducted
in patients with full thickness rotator cuff tear, which
was a specific exclusion criterion for our study, so the
results, although positive, are not of relevance to our
study population.
There has been some concern that subacromial cortico-
steroid injections could be detrimental to the recovery of
the rotator cuff tendon. Animal studies have shown detri-
mental effects of repeated corticosteroid injections on the
rotator cuff of rats. Consequent damage to the ultrastruc-
ture of collagen molecules has been shown experimentally
to weaken collagen fibers and precipitate rotator cuffinjuries, with authors suggesting that this could translate
into humans, so caution should be exercised [23-25].
However, a study by Bhatia et al. [26] suggests that cor-
ticosteroid use in patients with subacromial impingement
should not be considered a causative factor in rotator cuff
tears. This retrospective, case-controlled study compared
patients with subacromial impingement syndrome accord-
ing to the number of subacromial corticosteroid injections
they had received (less than three versus three or more).
Analysis by magnetic resonance imaging (MRI) showed
no significant difference between the two groups in the
incidence of rotator cuff tear (p < 1.0).
These concerns serve to highlight the potential need for
an effective and safe treatment for rotator cuff syndrome
that is not associated with potential detrimental effects on
the rotator cuff tendon. In a previous non-randomized,
observational study, Tr14 injection solution injections
were found to be non-inferior to NSAID injections (mainly
diclofenac) for the treatment of epicondylitis [15]. Although
the study was designed to demonstrate non-inferiority,
markedly greater improvements in pain at rest, change in
extensional joint mobility and change in torsional joint
mobility were observed, along with greater satisfaction and
better tolerability reports from patients for Tr14 injection
solution versus NSAID injections. This current study has
been designed to investigate whether Tr14 injection solu-
tion could provide an effective alternative to corticosteroids
with the potential for a better safety profile. This could
expand the range of treatments available to clinicians for
the treatment of rotator cuff syndrome, providing greater
patient choice.
The American Academy of Orthopaedic Surgeons
(AAOS) guidelines on ‘Optimizing the Management of
Rotator Cuff Problems’ state that they cannot recommend
for or against the use of subacromial corticosteroid injec-
tions in the treatment of rotator-cuff-related symptoms in
the absence of full thickness tear [27]. This is due to a lack
of compelling evidence resulting in an unclear balance
between benefits and potential harm. There is even less
evidence about the efficacy of natural medications. It is
hoped that the results of this trial will assist in providing
more evidence to support physicians in their management
of rotator cuff disease. Investigation of the efficacy and
place in therapy of Tr14 injection solution is ongoing with
further randomized-controlled trials underway.Abbreviations
AAOS: American academy of orthopaedic surgeons; AE: Adverse event;
ANCOVA: Analysis of covariance; CMH: Cochran-mantel-haenszel; COX: Cyclo-
oxygenase; COX-2: Cyclo-oxygenase type 2; DASH: Disability of arm: shoulder:
hand; EU: European union; GCP: Good clinical practice; GMP: Good
manufacturing practice; HbA1c: Glycosylated fraction of hemoglobin;
ICH: International conference on harmonization; IUD: Intrauterine device;
LOCF: Last observation carried forward; MedDRA: Medical dictionary for
regulatory activities; MRI: Magnetic resonance imaging; NSAID: Non-steroidal
anti-inflammatory drug; ROM: Range of motion; TENS: Transcutaneous
Vanden Bossche and Vanderstraeten BMC Musculoskeletal Disorders  (2015) 16:8 Page 9 of 9electrical nerve stimulation; Tr14: Traumeel; VAS: Visual analog scale;
WHO: World Health Organization; WMA: World medical assembly.
Competing interests
Luc Vanden Bossche (LVB) is a consultant/advisor to the Traumeel Scientific
Advisory Board for Biologische Heilmittel Heel GmbH. LVB is receiving
honorarium for work on this study. LVB and has received honoraria for
giving scientific talks on behalf of Biologische Heilmittel Heel GmbH. Guy
Vanderstraeten (GV) is a consultant/advisor to Biologische Heilmittel Heel
GmbH.
Authors’ contributions
LVB is principal investigator. LVB contributed to the overall design of the
study and helped draft the protocol. GV is the medical advisor in the study.
GV contributed to the overall design of the study and helped draft the
protocol. All authors revised the manuscript critically for important
intellectual content and have given final approval of the version to be
published.
Authors’ information
LVB: I have been treating patients with musculoskeletal injuries for over
10 years. In this time the number of patients presenting to me who are
unable to use NSAIDs, corticosteroids or other traditional medications has
increased. This is often due to contraindications and intolerance to the
products. As a physician, I would like to offer my patients an alternative
option that is both safe and effective. I have participated in this trial in the
hope that Tr14 injection solution may provide such an option.
Acknowledgements
This study is sponsored by Biologische Heilmittel Heel GmbH, Baden-Baden,
Germany. Study management, data analysis, editorial support and manuscript
charges were funded by Biologische Heilmittel Heel GmbH. The authors
would like to thank Ann Stringer for assistance in the preparation of the
manuscript and Anna Roubo, Aspen Medical Media, for editorial assistance
on behalf of Biologische Heilmittel Heel GmbH.
Author details
1Physical and Rehabilitation Medicine, Sportsmedicine, Ghent University
Hospital, De Pintelaan 185, 9000 Ghent, Belgium. 2Department of
Rehabilitation Sciences and Physical Therapy, Faculty of Medicine and Health
Sciences, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Received: 23 April 2014 Accepted: 15 January 2015
References
1. Rekola KE, Keinanen-Kiukaanniemi S, Takala J. Use of primary health services
in sparsely populated country districts by patients with musculoskeletal
symptoms: consultations with a physician. J Epidemiol Community Health.
1993;47:153–7.
2. Gomoll AH, Katz JN, Warner JP, Millett PJ. Rotator cuff disorders. Recognition
and management among patients with shoulder pain. Arthritis Rheum.
2004;50:3751–61.
3. Praemer A, Furner S, Rice D. Musculoskeletal conditions in the United States.
2nd ed. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1999.
4. Goldberg BA, Nowinski RJ, Matsen 3rd FA. Outcome of nonoperative
management of full thickness rotator cuff tears. Clin Orthop Relat Res.
2001;382:99–107.
5. Varthi A, Piposar J, Chan W, Blaine TA. Upper extremity: biologic treatments
for shoulder pain. Curr Orthop Pract. 2013;24:360–4.
6. Coghlan JA, Buchbinder R, Green R, Johnston RV, Bell SN. Surgery for rotator
cuff disease. Cochrane Database Syst Rev. 2008;1:CD005619.
7. Galatz LM, Griggs S, Cameron BD, Iannotti JP. Prospective longitudinal
analysis of postoperative shoulder function: a ten-year follow-up study of
full-thickness rotator cuff tears. J Bone Joint Surg Am. 2001;83:982–9.
8. Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain.
Cochrane Database Syst Rev. 2003;1:CD004016.
9. Arroll B, Goodyear-Smith F. Corticosteroid injections for painful shoulder: a
meta-analysis. Br J Gen Pract. 2005;55:224–8.10. Henkus H-E, Cobben LPJ, Coerkamp EG, Nelissen RGHH, van Arkel ERA.
The accuracy of subacromial injections: a prospective randomized magnetic
resonance imaging study. J Arthrosc Relat Surg. 2006;22:277–82.
11. Marder RA, Kim SH, Labson JD, Hunter JC. Injection of the subacromial
bursa in patients with rotator cuff syndrome: a prospective, randomized
study comparing the effectiveness of different routes. J Bone Joint Surg Am.
2012;94:1442–7.
12. Cesnulevicius K. The bioregulatory approach to work-related musculoskeletal
disorders: using the multicomponent ultra low-dose medication Traumeel
to target the multiple pathophysiological processes of the disease.
Altern Ther Health Med. 2011;17 Suppl 2:S8–17.
13. Lussignoli S, Bertani S, Metelmann H, Bellavite P, Conforti A. Effect of
Traumeel S®, a homeopathic formulation, on blood-induced inflammation
in rats. Complement Ther Med. 1999;7:225–30.
14. Thiel W. The treatment of recent traumatic blood effusions of the knee
joint. Biol Ther. 1994;XII:242–8.
15. Birnesser H, Oberbaum M, Klein P, Weiser M. The homeopathic preparation
Traumeel compared with NSAIDs for symptomatic treatment of
epicondylitis. J Musculoskel Res. 2004;2(3):119–28.
16. Schneider C, Schneider B, Hanisch J, van Haselen R. The role of a
homoeopathic preparation compared with conventional therapy in the
treatment of injuries: an observational cohort study. Complement Ther Med.
2008;16:22–7.
17. Article 1(5) of Directive 2001/83/EC as amended by 2004/27/EC [http://
www.homeopathyeurope.org/european-union/eu-regulations/homeopathic-
medicines-1/Directive%202004-27-EC.pdf]
18. Moen MH, De Vos RJ, van Arkel ERA, Weir A, Moussavi J, Kraan T, et al.
De meest waardevolle klinische schoudertesten, een literatuuroverzicht.
Sport Geneesk. 2008;4:1–14.
19. Woodward TW, Best TM. The painful shoulder. Part I clinical evaluation.
Am Fam Physician. 2000;61:3079–88.
20. Stephens MB, Beutler AI, O’Connor FG. Musculoskeletal injections: a review
of the evidence. Am Fam Physician. 2008;78:971–6.
21. Plafki C, Steffen R, Willburger RE, Wittenberg RH. Local anaesthetic injection
with and without corticosteroids for subacromial impingement syndrome.
Int Orthop. 2000;24:40–2.
22. Shibata Y, Midorikawa K, Emoto G, Naito M. Clinical evaluation of sodium
hyaluronate for the treatment of patients with rotator cuff tear. J Shoulder
Elbow Surg. 2001;10:209–16.
23. Tillander B, Franzen LE, Karlsson MH, Norlin R. Effect of steroid injections on
the rotator cuff: an experimental study in rats. J Shoulder Elbow Surg.
1999;8:271–4.
24. Wei AS, Callaci JJ, Juknells D, Marra G, Tonino P, Freedman KB, et al.
The effect of corticosteroid on collagen expression in injured rotator cuff
tendon. J Bone Joint Surg Am. 2006;88:1331–8.
25. Lee HJ, Kim YS, Ok JH, Lee YK, Ha MY. Effect of a single subacromial
prednisolone injection in acute rotator cuff tears in a rat model. Knee Surg
Sports Traumatol Arthrosc 2013, Jan 31 epub ahead of print.
26. Bhatia M, Singh B, Nicolaou N, Ravikumar KJ. Correlation between rotator
cuff tears and repeated subacromial steroid injections: a case-controlled
study. Ann R Coll Surg Engl. 2009;91:414–6.
27. American Academy of Orthopaedic Surgeons. Optimizing the management
of rotator cuff problems. Guideline and evidence report. Rosemont, IL:
American Academy of Orthopaedic Surgeons; 2010 [http://www.aaos.org/
research/guidelines/RCP_guideline.pdf]
